[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subcutaneous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subcutaneous":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100641127","phase-3-subcutaneous-calcitonin-in-acute-herpes-zoster-100641127",false,"NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.","ALL","50 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[26,27,28],"Calcitonin","Subcutaneous","Acute Herpes Zoster","NOT_YET_RECRUITING","2026-06-13",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2027-10-01",{"name":39,"class":40},"Tanta University","OTHER"]